Mesoblast Limited (NASDAQ:MESO - Get Free Report) shares crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $11.57 and traded as low as $10.60. Mesoblast shares last traded at $10.85, with a volume of 106,288 shares traded.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on MESO. Cantor Fitzgerald raised Mesoblast to a "strong-buy" rating in a research report on Monday, March 31st. Piper Sandler reaffirmed an "overweight" rating and set a $24.00 price objective (up from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $18.00.
View Our Latest Stock Report on Mesoblast
Mesoblast Price Performance
The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The stock has a 50-day simple moving average of $11.46 and a 200 day simple moving average of $13.96.
Hedge Funds Weigh In On Mesoblast
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC grew its stake in shares of Mesoblast by 70.9% in the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock worth $43,000 after acquiring an additional 901 shares during the last quarter. R Squared Ltd bought a new stake in Mesoblast in the 4th quarter valued at $30,000. Prosperity Wealth Management Inc. grew its position in Mesoblast by 2.0% in the 4th quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company's stock worth $1,846,000 after purchasing an additional 1,795 shares during the last quarter. Quadrant Capital Group LLC increased its holdings in shares of Mesoblast by 41.1% during the 4th quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company's stock worth $129,000 after purchasing an additional 1,891 shares during the period. Finally, Barclays PLC acquired a new position in shares of Mesoblast during the fourth quarter valued at about $38,000. Institutional investors and hedge funds own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Read More
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
